New Delhi, Dec 31 (PTI) Drug maker Lupin Monday said it has received approval from the US health regulator for Clobazam Oral Suspension, used to treat seizures associated with Lennox-Gastaut Syndrome. Also Read - Trump Skips G20 Summit on Pandemic Preparedness, Later Spotted at His Golf Course: Report

The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, Lupin said in a regulatory filing. Also Read - Won’t Let Rigged Election Steal Our Country: Trump Takes U-turn After Acknowledging Biden’s Victory

The drug is indicated for treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients of two years of age or older. Also Read - US Election 2020 Results: Biden Leads in Pennsylvania, Votes in Georgia to be Recounted

Clobazam Oral Suspension (2.5 mg/ml) had annual sales of around USD 260.2 million in the US.

Lupin shares Monday ended 0.78 per cent up at Rs 845.60 apiece on the BSE.

This is published unedited from the PTI feed.